Matteo Scarabelli
Associate Director, Market Access, EFPIA
After a PhD in Philosophy and a first experience in a competitiveness-focus Brussels think tank, Matteo Scarabelli has been responsible for the involvement of patients in Regulatory approval and HTA/access decisions for orphan drugs. He contributed designing the strategy of rare disease organisations across Europe for the new EU HTA for almost five years, also participating in the genesis and in the inter-institutional negotiations of the HTA Regulation. For two years now, he has been working at the heart of the pharmaceutical industry’s efforts to prepare for the new European HTA setting and its implementation into national pricing and reimbursement systems, as EFPIA—European Federation Pharma Industries Associations—Associate Director for Market Access.